Comparison of traditional and next-generation oral anticoagulants in the etiology of epistaxis: Traditional and novel anticoagulants in epistaxis

Süheyla Kandemir; Hüseyin Kandemir

doi:10.28982/josam.7852

Authors

Süheyla Kandemir Department of Otorhinolaryngology, Kırıkkale University, Faculty of Medicine, Kırıkkale, Turkey https://orcid.org/0000-0003-3354-2212
Hüseyin Kandemir Department of Cardiology, Kırıkkale University, Faculty of Medicine, Kırıkkale, Turkey https://orcid.org/0000-0002-4462-7425

DOI:

https://doi.org/10.28982/josam.7852

Keywords:

Epistaxis, Anticoagulants, Warfarin, Rivaroxaban, Dabigatran

Abstract

Background/Aim: There is a dearth of studies addressing the effects of next-generation anticoagulants on epistaxis. The aim of this investigation was to determine whether there are any differences between traditional and next-generation anticoagulants in the etiology of epistaxis.

Methods: This retrospective cohort study focused on a total of 7,110 individuals (3,278 females (46.1%) and 3,832 males (53.9%)) diagnosed with epistaxis between 2018 and 2022; the mean age of the patients was 37.7 years. Patient data (age, gender, outpatient and inpatient treatments, relevant laboratory parameters, and treatment evidence) were retrospectively reviewed from a hospital database. The severity of epistaxis was assessed based on treatment notes. Patients with hypertension and those undergoing antiaggregant therapy were excluded from the study. International Classification of Diseases (ICD) codes from the automated system were examined retrospectively. The data were used to establish three patient groups: the first group consisted of individuals taking next-generation oral anticoagulants, the second group consisted of individuals taking traditional oral anticoagulants, and the third group consisted of healthy controls.

Results: We found statistically significant differences among the groups in terms of age, the severity of epistaxis, the treatment modality, and laboratory findings (P<0.001); no statistically significant difference was found in terms of gender (P=0.954). Group 2 contained the largest number of hospitalized patients and patients with severe active nosebleeds.

Conclusion: Next-generation anticoagulants are more reliable than traditional anticoagulants in terms of the severity of epistaxis, the need for hospitalization, and laboratory results.

Downloads

Download data is not yet available.

References

Cohen O, Shoffel-Havakuk H, Warman M, Tzelnick S, Haimovich Y, Kohlberg GD, et al. Early and Late Recurrent Epistaxis Admissions: Patterns of Incidence and Risk Factors. Otolaryngol Head Neck Surg. 2017;157:424-31. DOI: https://doi.org/10.1177/0194599817705619

Krulewitz NA, Fix ML. Epistaxis. Emerg Med Clin North Am. 2019;37:29-39. DOI: https://doi.org/10.1016/j.emc.2018.09.005

Neshewat J, Wasserman A, Alexandris-Souphis C, Haymart B, Feldeisen D, Kong X, et al. Reduction in epistaxis and emergency department visits in patients taking warfarin after implementation of an education program. Thromb Res. 2021;199:119-22. DOI: https://doi.org/10.1016/j.thromres.2021.01.007

Douglas R, Wormald PJ. Update on epistaxis. Curr Opin Otolaryngol Head Neck Surg. 2007;15:180-3. DOI: https://doi.org/10.1097/MOO.0b013e32814b06ed

Sowerby LJ, DeSerres JJ, Rudmik L, Wright ED. Role of season, temperature and humidity on the incidence of epistaxis in Alberta, Canada. J Otolaryngol Head Neck Surg. 2014;43:10. DOI: https://doi.org/10.1186/1916-0216-43-10

Tunkel DE, Anne S, Payne SC, Ishman SL, Rosenfeld RM, Abramson PJ, et al. Clinical Practice Guideline: Nosebleed (Epistaxis). Otolaryngol Head Neck Surg. 2020;162:1-38. DOI: https://doi.org/10.1177/0194599819890327

Chaaban MR, Zhang D, Resto V, Goodwin JS. Demographic, seasonal, and geographic differences in emergency department visits for epistaxis. Otolaryngol Head Neck Surg. 2017;156:81-6. DOI: https://doi.org/10.1177/0194599816667295

Purkey MR, Seeskin Z, Chandra R. Seasonal variation and predictors of epistaxis. Laryngoscope. 2014;124:2028–33. DOI: https://doi.org/10.1002/lary.24679

Riviello RJ. Otolaryngologic procedures. In: Clinical Procedures in Emergency Medicine, 4th, Roberts JR, Hedges JR (Eds), WB Saunders, Philadelphia, 2004; p.1300

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. DOI: https://doi.org/10.1056/NEJMoa1009638

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. DOI: https://doi.org/10.1056/NEJMoa0905561

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. DOI: https://doi.org/10.1056/NEJMoa1107039

Pallin DJ, Chng YM, McKay MP, Emond JA, Pelletier AJ, Camargo CA Jr. Epidemiology of epistaxis in US emergency departments, 1992 to 2001. Ann Emerg Med. 2005;46:77-81. DOI: https://doi.org/10.1016/j.annemergmed.2004.12.014

Viehweg TL, Roberson JB, Hudson JW. Epistaxis: diagnosis and treatment. J Oral Maxillofac Surg. 2006;64:511-8. DOI: https://doi.org/10.1016/j.joms.2005.11.031

Seidel DU, Sesterhenn AM, Kostev K. Seasonal Variation of Epistaxis in Germany. J Craniofac Surg. 2018;29:365-7. DOI: https://doi.org/10.1097/SCS.0000000000004351

Huang CL, Shu CH. Epistaxis: a review of hospitalized patients. Zonghua Yi Xue Za Zhi (Taipei). 2002;65:74-8.

Bermüller C, Bender M, Brögger C, Petereit F, Schulz M. Epistaxis and anticoagulation - a medical and economic challenge? Laryngorhinootologie. 2014;93:249-55. DOI: https://doi.org/10.1055/s-0033-1355400

Andreotti F, Rocca B, Husted S, Ajjan RA, ten Berg J, Cattaneo M, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2015;36:3238–49. DOI: https://doi.org/10.1093/eurheartj/ehv304

Ho JPK, Bari N, Riffat F. Management of epistaxis in patients on novel oral anticoagulation therapy. J Laryngol Otol. 2020;134:316-22. DOI: https://doi.org/10.1017/S0022215120000754

Buchberger AMS, Baumann A, Johnson F, Peters N, Piontek G, Storck K, et al. The role of oral anticoagulants in epistaxis. Eur Arch Otorhinolaryngol. 2018;275:2035-43. DOI: https://doi.org/10.1007/s00405-018-5043-z

Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74–81. DOI: https://doi.org/10.1124/dmd.108.023143

Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest. 2012;141:120–51. DOI: https://doi.org/10.1378/chest.11-2294

Suzuki S, Otsuka T, Sagara K, Semba H, Kano H, Matsuno S, et al. Nine-year trend of anticoagulation use, thromboembolic events, and major bleeding in patients with non-valvular atrial fibrillation- shinken database analysis. Circ J. 2016;80:639–49. DOI: https://doi.org/10.1253/circj.CJ-15-1237

Rubboli A, Becattini C, Verheugt FW. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol. 2011:3:351–8. DOI: https://doi.org/10.4330/wjc.v3.i11.351

Gomes P, Salvador P, Lombo C, Caselhos S, Fonseca R. Role of age and anticoagulants in recurrent idiopathic epistaxis. Acta Otorrinolaringol Esp. 2020;71:160-5. DOI: https://doi.org/10.1016/j.otorri.2019.05.003

L’Huillier V, Badet C, Tavernier L. Epistaxis complicating treatment by anti-vitamin K and new oral anticoagulants. Eur Ann Otorhinolaryngol Head Neck Dis 2018;135:231–5. DOI: https://doi.org/10.1016/j.anorl.2018.04.006

Sauter TC, Hegazy K, Hautz WE, Krummrey G, Ricklin ME, Nagler M, et al. Epistaxis in anticoagulated patients: fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. Clin Otolaryngol. 2018;43:103–8. DOI: https://doi.org/10.1111/coa.12904

Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, et al. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2016;116:544–53. DOI: https://doi.org/10.1160/TH15-12-1000

Gökdogan O, Akyildiz I, Sayin BY, Okutucu S, Tanalp AC, Arslan N. The rate of epistaxis incidence in new generation anticoagulants and perioperative approach in otorhinolaryngological practices. J Craniofac Surg. 2017;28:178–82. DOI: https://doi.org/10.1097/SCS.0000000000003135

Send T, Bertlich M, Horlbeck F, Schafigh D, Freytag S, Eichhorn KW, et al. Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin. Int Forum Allergy Rhinol. 2019;9:120–4. DOI: https://doi.org/10.1002/alr.22210

Yaniv D, Zavdy O, Sapir E, Levi L, Soudry E. The impact of traditional anticoagulants, novel antikoagulants and antiplatelets on epistaxis. Laryngoscope. 2021;131:1946-51. DOI: https://doi.org/10.1002/lary.29417

Spielmann P, Barnes M, White P. Controversies in the specialist management of adult epistaxis: an evidence-based review. Clin Otolaryngol. 2012;37:382–9. DOI: https://doi.org/10.1111/coa.12024

Sandoval C, Dong S, Visintainer P, Ozkaynak MF, Jayabose S. Clinical and laboratory features of 178 children with recurrent epistaxis. J Pediatr Hematol Oncol. 2002;24:47–9. DOI: https://doi.org/10.1097/00043426-200201000-00013

Thaha M, Nilssen E, Holland S, Love G, White PS. Routine coagulation screening in the management of emergency admission for epistaxis – is it necessary? J Laryngol Otol. 2000;114:38–40. DOI: https://doi.org/10.1258/0022215001903861

Béquignon E, Teissier N, Gauthier A, Brugel L, De Kermadec H, Coste A, et al. Emergency department care of childhood epistaxis. Emerg Med J. 2017;34:543–8. DOI: https://doi.org/10.1136/emermed-2015-205528

Horton JD, Bushwick B. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 1999;59:635–46.